Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heated versus normothermic intraperitoneal cisplatin during interval debulking surgery for ovarian cancer
ACTRN12621000269831Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by The University of Sydney. Primary endpoint: Grade 3-5 surgical adverse events. Started Mar 2022; status: completed.
02
Drugs
cisplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12621000269831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000269831.